IQVIA (NYSE:IQV) Given New $250.00 Price Target at Morgan Stanley

IQVIA (NYSE:IQV) had its price target hoisted by Morgan Stanley from $245.00 to $250.00 in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock.

Several other research firms have also recently issued reports on IQV. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.67.

IQVIA Stock Performance

NYSE:IQV opened at $200.94 on Tuesday. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a 50 day simple moving average of $200.77 and a 200-day simple moving average of $219.09. The firm has a market cap of $36.47 billion, a PE ratio of 26.79, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts expect that IQVIA will post 10.81 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IQV. Raymond James Financial Inc. bought a new position in IQVIA in the fourth quarter worth about $236,120,000. American Century Companies Inc. lifted its holdings in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after purchasing an additional 905,960 shares during the last quarter. FMR LLC boosted its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA in the third quarter worth $147,683,000. Finally, JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.